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AnalyWHAT THIS PAPER ADDS
This meta-analysis, including 14 studies, compared carotid artery uptake in symptomatic versus asymptomatic
disease, and demonstrated a significantly higher tracer uptake in symptomatic disease. Although PET/CT imaging
in atheroma is a research tool and is currently limited in its clinical applicability, it may provide information
about plaque biology, and therefore in the future, risk of stroke in carotid disease patients.Introduction: The role of positron emission tomography (PET)/computed tomography (CT) in the determination
of inflammation in arterial disease is not well defined. This can provide information about arterial wall
inflammation in atherosclerotic disease, and may give insight into plaque stability. The aim of this review was to
perform a meta-analysis of PET/CT with 18F-FDG (fluorodeoxyglucose) uptake in symptomatic and asymptomatic
carotid artery disease.
Methods: This was a systematic review, following PRISMA guidelines, which interrogated the MEDLINE database
from January 2001 to May 2017. The search combined the terms, “inflammation”, “FDG”, and “stroke”. The search
criteria included all types of studies, with a primary outcome of the degree of arterial vascular inflammation
determined by 18F-FDG uptake. Analysis involved an inverse weighted variance estimate of pooled data, using a
random effects model.
Results: A total of 14 articles (539 patients) were included in the meta-analysis. Comparing carotid artery 18F-FDG
uptake in symptomatic versus asymptomatic disease yielded a standard mean difference of 0.94 (95% CI 0.58e
1.130; p < .0001; I2 ¼ 65%).
Conclusions: PET/CT using 18F-FDG can demonstrate carotid plaque inflammation, and is a marker of
symptomatic disease. Further studies are required to understand the clinical implication of PET/CT as a risk
prediction tool.
 2018 The Authors. Published by Elsevier B.V. on behalf of European Society for Vascular Surgery. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Article history: Received 7 December 2017, Accepted 29 March 2018, Available online XXX
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Atherosclerosis related cardiovascular disease is a major
global health problem, and is the leading cause of death in
every region of the world.1 Alongside myocardial infarction,
stroke is a major cause of mortality and morbidity.se authors are joint senior authors of the paper.
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sis, European Journal of Vascular and Endovascular Surgery (2018), httpApproximately 80% of strokes are ischaemic in nature, with
the carotid artery deemed the embolic source in 10%. There
is strong evidence that early carotid endarterectomy is key
in reducing stroke rates in patients with significant symp-
tomatic ipsilateral carotid disease,2 whereas asymptomatic
disease is increasingly managed by conservative treatment
(best medical therapy).3 Only a small proportion of
asymptomatic patients with a significant carotid artery
stenosis will develop a stroke or transient ischaemic attack
(TIA) and as such the key is to identify those patients with
an “at risk” plaque who could then be offered carotid
endarterectomy.4
Atherosclerotic plaques, formed because of a build up of
lipids and inflammatory cells within the arterial wall, oftenn PET/CT in Symptomatic versus Asymptomatic Carotid Disease: a Meta-
s://doi.org/10.1016/j.ejvs.2018.03.028
2 Mohammed M. Chowdhury et al.occur in areas of low sheer stress, including arterial bi-
furcations, as the disturbed blood flow increases the
expression of cellular transcription factors and adhesion
molecules responsible for recruiting circulating mono-
cytes.5,6 High risk plaque characteristics include a thin fibrous
cap, inflammatory cell infiltration, large lipid core, paucity of
smooth muscle cells, and microcalcification. Mechanisms
determining transition of high risk plaques to either a more
stable phenotype or to plaque rupture are incompletely
understood; however, inflammation is increasingly recog-
nised as a precipitant for plaque rupture, which within the
carotid circulation results in symptomatic embolic conse-
quences, namely transient ischaemic attacks or stroke.7
Positron emission tomography (PET) is a nuclear imaging
technique with a high sensitivity, meaning that it can detect
picomolar concentrations of a tracer (a radiolabelled ligand)
of interest. As the tracer decays, an annihilation reaction
produces photons. The release of gamma radiation is
detected by the PET scanner and used to create a tomo-
graphic map of tracer distribution within the body. A
common measure of tracer uptake used to determine tracer
activity is the standardised uptake value (SUV). When SUV is
corrected for blood pool activity (the circulating level of
tracer in the venous system), this is termed the tissue to
background ratio (TBR).
Fluorodeoxyglucose (18F-FDG) is a radiolabelled glucose
analogue, which is taken up by all glucose metabolising cells.
Specifically, FDG competes with endogenous glucose for
facilitated transport sites (GLUT-1 and GLUT-3). After phos-
phorylation FDG becomes trapped within the cells it has
entered as it lacks the necessary 20 hydroxyl group needed to
advance in the glycolytic pathway. Macrophages are active in
the atherosclerotic plaque and can metabolise free fatty
acids, but in the plaque, they prefer glucose: activated
macrophages have an increased expression of GLUT-1 and -3
receptors. FDG uptake is therefore a function of macrophage
density and activation, and therefore plaque activity.8
The evidence base for PET/CT imaging in arterial disease
is continually developing in a number of vascular beds. The
ease of imaging the carotid artery using a number of
techniques, the availability of atherosclerotic plaques for
histological interrogation as a result of carotid endarterec-
tomy and the devastating consequence of stroke make the
carotid artery a pertinent one to study. As such, this meta-
analysis focuses on how, specifically 18F-FDG PET/CT imag-
ing can be applied to carotid artery atherosclerosis.
METHODS
This study followed the Preferred Reporting Items for Sys-
tematic Reviews (PRISMA) checklist.9 Ethics committee
approval was not required as the study was a systematic
review/meta-analysis. The study is a meta-analysis evalu-
ating the role of 18F-FDG PET/CT imaging in patients with
carotid artery atherosclerotic disease. The primary outcome
was to determine differences in 18F-FDG tracer uptake be-
tween significant symptomatic and asymptomatic carotid
stenosis.Please cite this article in press as: Chowdhury MM, et al., 18F-FDG Uptake o
Analysis, European Journal of Vascular and Endovascular Surgery (2018), httpsSearch strategies
An electronic search was undertaken using EMBASE and
PUBMED to search the MEDLINE database from January
2001 to May 2017. The search combined the terms,
“inflammation”, “FDG”, and “stroke”.
Search criteria
Inclusion criteria comprised all study types including rand-
omised controlled, cohort, caseecontrol, case series, and
experimental studies with human subjects undergoing PET/
CT scans examining carotid disease in at least five patients.
Studies were excluded if they, included coronary or aortic
analysis of PET/CT imaging, involved imaging within ani-
mals, studies of vasculitis, or if the study did not provide
clinical data (symptomatology). Furthermore, studies were
also excluded if they examined carotid uptake in the
absence of carotid atherosclerosis.
Data extraction and synthesis
Data were extracted by one researcher (M.M.C.) and
checked by another researcher (J.M.T.) using a standardised
data capture form developed prior to the onset of the
study. Disagreements were resolved by re-extraction or by
third party adjudication (P.A.C.) when necessary.
Collected study characteristics included number of sub-
jects undergoing PET/CT and number of centres involved in
the study. Furthermore, patient population, dose of FDG
injected, uptake time, imaging protocols, primary endpoint
measures for PET/CT, and the main findings were all
collected and tabulated, as per published guidance.10
Statistical analysis
Estimation of the global effect for the primary outcome for
carotid disease (18F-FDG uptake in symptomatic versus
asymptomatic plaques) was assessed through an inverse
variance weighted estimate of the pooled data (where
applicable), using the random effects model. Given the
continuous nature of data (SUVmax/TBRmax) application of
the ManteleHaenszel method was used. The standardised
mean difference was used given the variability in reporting
outcomes (SUV and TBR). Analysis was performed using
Review Manager Analysis software (RevMan 5.3.5, Nordic
Cochrane Centre, Copenhagen, Denmark).
RESULTS
Included studies
A total of 50 titles were initially identified from the search
and their titles and abstracts were screened (Fig. 1). Of
those, 29 were excluded as they failed to meet the inclusion
criteria. The remaining 21 were assessed for eligibility via
full text review. Two studies were then excluded because of
being (earlier) replicated studies and a further study
excluded because of inadequate reporting of objective
outcome data, and have not been presented in the citation
list. Four articles did not have a direct comparison ofn PET/CT in Symptomatic versus Asymptomatic Carotid Disease: a Meta-
://doi.org/10.1016/j.ejvs.2018.03.028
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Figure 1. Flow diagram of systematic review synthesis.
18F-FDG PET/CT in Carotid Disease 3symptomatic versus asymptomatic disease. The remaining
14 articles were included in the meta-analysis and form the
study population analysed (PRISMA Flow Chart; Fig. 1). The
total number of patients identified from the included
studies was 539 (268 symptomatic, 271 asymptomatic). The
mean 18F-FDG injected dose was 306.3  91.4 MBq.18F-FDG tracer uptake in symptomatic and asymptomatic
carotid disease
A total of 539 patients were included within this analysis
(mean age 71.2  3.5, 76% male). Pooled comparisons of
studies that analysed a difference in symptomatic versus
asymptomatic carotid atherosclerotic disease demonstrated
that 18F-FDG tracer uptake was significantly higher in
symptomatic carotid lesions (standard mean difference
0.94; 95% CI 0.58e1.30; p < .0001; I2 ¼ 65%, Fig. 2). A
summary of study details is shown in Table 1.11e24
DISCUSSION
This study is the first to systematically review and eval-
uate the role of 18F-FDG imaging of inflammation within
carotid artery atherosclerotic disease. The findings
demonstrate that 18F-FDG accurately differentiatesPlease cite this article in press as: Chowdhury MM, et al., 18F-FDG Uptake o
Analysis, European Journal of Vascular and Endovascular Surgery (2018), httpbetween symptomatic and asymptomatic carotid plaques
and is validated to accurately image areas of high
inflammation within the symptomatic carotid atheroscle-
rotic plaque, validated by histological analysis. Rudd
et al.11 performed the first prospective validation study
using 18F-FDG PET/CT to detect and quantify vascular
inflammation. They observed significantly higher FDG
tracer uptake within symptomatic carotid plaques than
the contralateral asymptomatic carotid artery. Further
studies have continued to explore the role of PET/CT
imaging within the carotid plaque and the results form
this meta-analysis.
Currently, the indication for carotid intervention is an
ipsilateral neurovascular event with a >50% internal ca-
rotid artery stenosis (NASCET criteria, ESC Guidelines25).
Even in patients with stenosis >70%, the number needed
to treat (NNT; defined as the number of patients who
would have to undergo carotid endarterectomy in order to
prevent one long-term adverse event) is six for patients
with 70e99% stenosis and 15 for patients with 50e69%
stenosis.26 As such, significant numbers of patients un-
dergo potentially needless and high risk surgery. PET/CT
imaging could play a role in specific risk stratification for
these patients, aiding clear identification of an activen PET/CT in Symptomatic versus Asymptomatic Carotid Disease: a Meta-
s://doi.org/10.1016/j.ejvs.2018.03.028
Figure 2. Forest plot for analysis of 18F-FDG uptake in symptomatic versus asymptomatic carotid disease (p < .00001).
4 Mohammed M. Chowdhury et al.carotid plaque comparison with patients who may have
non-carotid causes of symptoms.
More debatable is the role of intervention in patients
with a significant yet asymptomatic carotid stenosis. Data
from randomised trials shows that surgery confers an ab-
solute risk reduction in stroke of approximately 5%,
equating to a NNT of approximately one in 40. There are a
number of clinical and imaging features that may identify
those patients with a higher rate of stroke despite optimal
medical therapy yet because of the small event rate, large
scale screening studies will be needed to prove validity
which may limit the role of PET/CT imaging in part due to
radiation exposure. This can be overcome with PET/mag-
netic resonance imaging.27 PET imaging provides the
advanced molecular imaging, with high sensitivities, that
mainstream vascular imaging modalities do not offer.28 The
heterogeneity of the data included in this analysis (as dis-
cussed below) means that it is difficult to ascertain the cut
off value for 18F-FDG uptake (TBR/SUV) that defines a “high
risk plaque”. Many of the reported studies do not report
individual patient 18F-FDG uptake values, rendering inter-
pretation of the role of PET/CT imaging in asymptomatic
disease ambiguous at best. While the larger longitudinal
studies studying arterial inflammation have tended to focus
on non-atherosclerotic oncological populations, this means
that there is still a need for a large longitudinal prospective
study of asymptomatic patients to assess the truly predic-
tive role of 18F-FDG PET imaging in progression of carotid
disease activity.29
Pharmacotherapy trials have demonstrated both positive
and negative effects on signal uptake in carotid atheroma,30
yet there are further successful trials that have used PET/CT
as an imaging biomarker in other arterial beds, for example
the aorta and iliac vessels,31 and it is likely to be that such
imaging has distinct advantages as an outcome measure.
It is recognised that this field of research is still in its
infancy and understanding the role of molecular imaging in
atherosclerotic risk stratification is continuing. Owing to a
lack of large adequately powered studies, the formal
assessment was varied and generally poor due to insuffi-
cient data. Furthermore, another limitation to the included
data is the lack of reporting the time relationship between
imaging and symptom onset. This was only presented inPlease cite this article in press as: Chowdhury MM, et al., 18F-FDG Uptake o
Analysis, European Journal of Vascular and Endovascular Surgery (2018), httpseight out of the 14 studies, and requires clarification with
further molecular carotid imaging studies.
Of note, one ever evolving aspect in PET research
methodology is the optimisation of imaging protocols with
respect to the assessment of atheroma (variation across
included studies; Table 1). Publication of a recent position
paper32 by the European Association of Nuclear Medicine
on PET imaging in atherosclerosis has led to the creation of
technical recommendations when undertaking 18F-FDG PET.
These include an injected activity of between 3 and 4 MBq/
kg body weight, acquisition of PET images 120 min post
injection, and an ideal blood glucose level of less than 7.0e
7.2 mmol/L. It is evident that given this, more recent
studies are using these recommendations within their
protocol development and methodology.
The development of a number of novel tracers which
identify other pathological processes (hypoxia, neo-angio-
genesis24) alongside more specific markers of inflammation
(68Ga-DOTATATE)23 will continue to enhance the role of
molecular imaging. Specifically, there is now high quality
evidence regarding the role of the tracer 18FNaF (sodium
fluoride; a marker of microcalcification) in risk stratifying
atherosclerotic plaques within the coronary circulation
which is timely given the common issues of tracer overspill
within the myocardium which limits the role of 18F-FDG
within the coronary circulation.33 Similar data are now
available for 18F-FDG within the carotid circulation where
18F-FDG molecular imaging can highlight culprit high risk
carotid plaques, while also correlating strongly with pre-
dicted cardiovascular risk.22CONCLUSION
For over a decade, 18F-FDG PET/CT imaging in the carotid
circulation has provided an enhanced ability to study
atherosclerotic inflammation in symptomatic patients. The
studies presented here demonstrate that it is well validated,
reproducible, and may have the ability to differentiate
vulnerable plaque (in symptomatic patients) from more
stable plaque (in asymptomatic patients). 18F-FDG uptake is
significantly higher in symptomatic carotid disease than in
asymptomatic disease. Research methodologies are being
refined, and the role of PET/CT imaging in atheroma has then PET/CT in Symptomatic versus Asymptomatic Carotid Disease: a Meta-
://doi.org/10.1016/j.ejvs.2018.03.028
Table 1. Included study characteristics.
Study and design Population, age, average time
from symptoms to scan
Dose FGD
injected
Uptake time and protocol Primary endpoint measure Findings (FDG)
Rudd et al. 200211
Patient cohort study, IV
administration of 18F-FDG
with carotid disease, PET/CT,
histology
n ¼ 8 patients,
symptomatic disease (mean age
63.5, 75% male, 3.5 months)
370 MBq
over 60 s
190 min  6
Reconstructed images with 3D
re-projection, corrected for
attenuation
FDG accumulation rate, volumes
of interest (VOI)
Higher 18F-FDG PET/CT signals
in symptomatic versus
asymptomatic disease
(p ¼ .005) verified
histologically (CD68)
Davies et al. 200512
Prospective cohort study, IV
administration of 18F-FDG
with carotid disease, PET,
MRI
n ¼ 12 patients,
culprit carotid disease (mean age
71, 83% male, 64 days)
185 MBq 120 min
Reconstructed emission images
using PROMIS 3D filtered back
projection algorithm
Uptake ratio (FDG in plaque
divided by normal arterial wall
FDG)
Higher FDG uptake ratios in
symptomatic carotid disease
Arauz et al. 200713
Prospective cohort study, IV
administration of 18F-FDG
with carotid disease, PET/CT
n ¼ 13 patients,
high and low uptake (mean age
66.1, 69% male, 25 days)
370 MBq 90 min
6 h fast, image acquisition in 3D
mode, attenuated corrected
Standardised uptake values
(SUVs)
Patients with symptomatic
carotid disease had higher
FDG uptake, as well as with
stenosis (p  .001)
Kwee et al. 201114
Prospective cohort study, IV
administration of 18F-FDG
with carotid disease, PET/CT
n ¼ 50 patients,
symptomatic carotid disease
(mean age 67.8, 68% male, 33.3
days)
200 MBq 60 min
12 h fast, 3D mode, 120 kVp,
175 mAs, field of view
250  250 mm.
Standardised uptake values
(SUVs)
Significant correlation
between FDG signal and CT
characteristics in
symptomatic plaque
(p < .05)
Grandpierre et al. 201115
Retrospective, cohort study,
IV administration of FDG,
PET/CT
n ¼ 23 patient,
cancer patients admitted with
stroke due to carotid disease
(mean age 66, 86% male, 7
months)
400 MBq 60 min
6 h fast, 3D mode, 120 kV,
80 mAs, field of view
512  512 mm, 3 min per bed
position
Standardised uptake values
(SUVs)
Higher FDG uptake in patient
who had stroke in the carotid
artery was compared to no
stroke patients (p ¼ .006)
Marnane et al. 201216
Patient cohort study,
symptomatic stroke patients,
IV administration of 18F-FDG,
PET/CT
n ¼ 60 patients
13 recurrences (mean age 67.3,
85% male, 5 days)
47 no recurrence (mean age
71.6, 68% male, 7 days)
320 MBq 120 min
6 h fast, image acquired in 3D
mode, 2 bed positions for 10 min
Standardised uptake values
(SUVs)
Higher uptake of 18F-FDG in
patients with recurrent
strokes (p ¼ .02), mean
plaque FDG only predictor of
stroke recurrence (HR 6.1, 1.3
e28.8, p ¼ .02)
Muller et al. 201417
Patient cohort study,
symptomatic stroke patients,
IV administration of 18F-FDG,
PET/CT
n ¼ 123
60 symptomatic
63 asymptomatic (mean age 72,
76% male)
370 MBq 90 min
6 h fast, 3D mode, matric
336  336 pixels, attenuated
corrected
Target to background ratios
(TBRs)
Significantly higher FDG
uptake in symptomatic high
risk carotid plaques
(p < .0018)
Taqueti et al. 201418
Patient cohort study, IV
administration of 18F-FDG,
PET/CT, DCE-MRI
n ¼ 32 patients
symptomatic disease (mean age
68, 50% male)
370 MBq 90 min
3D list mode, in 1 bed position
over 20 min
Radiation exposure 8 mSv
Target to background ratios
(TBRs)
18F-FDG signals correlate
highly with markers of
macrophage density, in
symptomatic plaque
(p < .001)
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Table 1-continued
Study and design Population, age, average time
from symptoms to scan
Dose FGD
injected
Uptake time and protocol Primary endpoint measure Findings (FDG)
Shaikh et al. 201419
Patient cohort study, IV
administration of 18F-FDG, cf.
femoral plaque
n ¼ 35 patients
29 symptomatic carotid and 5
asymptomatic (mean age 67,
76% male)
185 MBq 60 min
6 h fast, 3D mode, 120 kV
attenuation correc. Radiation
27.4 mSv
Regions of interest (ROI) and hot
average
Significantly higher hot
average in symptomatic vs.
asymptomatic carotid
plaques (p ¼ .053)
Skagen et al. 201520
Prospective patient cohort
study, IV administration of
18F-FDG, PET/CT
n ¼ 36 patients
18 symptomatic, 18
asymptomatic
(mean age 67, 72% male)
370 MBq 90 min
6 h fast, 2D OSEM algorithm,
with matrix 256  256 pixels
Standardised uptake values
(SUVs)
Significantly higher hot
average in symptomatic
versus asymptomatic carotid
plaques (p ¼ .003)
Quirce et al. 201621
Prospective patient cohort
study, IV administration of
18F-FDG and 18FNaF, PET/CT
n ¼ 18 patients
9 symptomatic, 9 asymptomatic
(mean age 67, 88% male)
450 MBq 180 min
6 h fast, 5 min per bed space,
130 kV, 50 mAs 11.3 mSv
radiation dose
Standardised uptake values
(SUVs)
No significant difference in
FDG uptake in symptomatic
versus asymptomatic plaque
(p ¼ .85)
Vesey et al. 201722
Prospective case control
study, IV administration of
18F-FDG and NaF, high risk
plaque
n ¼ 26 patients
18 carotid group (mean age 71.7,
66.7% male)
8 control group (mean age 66.1,
50% male)
200 MBq 90 min
6 h fast, 3D mode, 120 kV, 2 bed
positions for 20 min per bed.
Target to background ratios
(TBRs)
18F-FDG higher uptake in
culprit vessel vs. control
(p ¼ .014), log10
transformed data
Tarkin et al. 201723
Prospective cohort study, IV
administration of 18F-FDG,
PET/CT, 68Ga-DOTATATE
n ¼ 28 patients
14 in carotid group (mean age
71, 75% male, 18 days)
14 in control (mean age 72.3,
76% male)
248.1 
22.3 MBq
90 min
6 h fast, 4 bed positions for
15 min, radiation 30 mSv, VUE FX
recons
Target to background ratios
(TBRs)
Significant uptake of FDG in
symptomatic plaques versus
control (p < .001)
Joshi et al. 201724
Prospective cohort study, IV
administration of 18F-FDG,
PET/CT, FMISO tracer
n ¼ 16 patients
8 patients in carotid group
(mean age 73, 70% male, 16
days)
8 patients control (mean age 71,
50% male)
250 MBq 120 min
6 h fast, one bed position for
15 min, 3D mode, VUE FX recons,
radiation 10.4 mSv
Target to background ratios
(TBRs)
Higher uptake of FDG in
culprit lesions (TBR 1.94
versus 1.90), despite p > .05
trend toward significance
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18F-FDG PET/CT in Carotid Disease 7reality of becoming a risk stratification tool. However, much
work is still required before its use in clinical practice. Cur-
rent data are limited predominantly to the carotid and cor-
onary circulation and as such focus needs to turn to other
vascular beds and specifically the lower limb arterial tree.FUNDING
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